World-leading capabilities in multiplexable gene editing
Join Our Team
Our Science
World-leading capabilities in multiplexable gene editing
Genome editing for immune-privileged features
Newsroom
Press Releases
Qihan Biotech's QT-019B Receives FDA RMAT and BTD2026/06/11
Qihan Biotech announced that its internally developed universal dual-target CAR-T therapy, QT-019B, has officially received both Regenerative Medicine Advanced Therapy (RMAT) designation and Breakthrough Therapy Designation (BTD) from the U.S. FDA.
1 / 3Press Releases
Qihan Biotech announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for QT-019C, a universal dual-target CAR-T candidate, marking a significant milestone in the development of a potentially optimized low-lymphodepletion, off-the-shelf CAR-T therapy for autoimmune diseases2026/05/15
Qihan Biotech announced today that QT-019C has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA).
1 / 3Press Releases
Qihan Biotech Initiates Dosing in Phase I/IIa Clinical Trial with Off-the-Shelf Allogeneic CAR-T Therapy for Refractory Systemic Lupus Erythematosus2025/12/16
QihanBiotech
1 / 3
Contact Us
Hangzhou Qihan Biotech Co., Ltd.
Address: Xiaoshan District, Hangzhou, Zhejiang, China
Zipcode: 311200
TEL: 0571-83500380
FAX: 0571-83500370